Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02816697 · ClinicalTrials.gov registry record · NA
Implementation of a System-level Tobacco Treatment Intervention
A NA study of Lung Cancer and Smoking Cessation, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 263
- Enrollment target
- 2
- Study locations
NCT02816697 is a NA study of Lung Cancer and Smoking Cessation that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 263 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02816697, a NA study of Lung Cancer and Smoking Cessation, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 263 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed study plans to adapt and study the implementation and effectiveness of integrating Clinical and Community Effort Against Secondhand smoke Exposure (CEASE) into the thoracic oncology setting using mixed methods.
Conditions Studied
Interventions
- OTHER CEASE
- OTHER Usual Care Tobacco Treatment Services
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2016-06 |
| Est. Completion | 2026-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02816697
The ClinicalTrials.gov registry entry for NCT02816697 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (72% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which CEASE is the first listed.
NCT02816697 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02816697 about?
NCT02816697 is a clinical study titled "Implementation of a System-level Tobacco Treatment Intervention". The proposed study plans to adapt and study the implementation and effectiveness of integrating Clinical and Community Effort Against Secondhand smoke Exposure (CEASE) into the thoracic oncology setting using mixed methods.
What is the current status of trial NCT02816697?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 263 participants. The study started on 2016-06. Estimated completion is 2026-02.
What conditions does trial NCT02816697 study?
This clinical trial studies the following conditions: Lung Cancer, Smoking Cessation.
What interventions are being tested in trial NCT02816697?
The interventions under investigation include: CEASE (OTHER), Usual Care Tobacco Treatment Services (OTHER).
Who is sponsoring clinical trial NCT02816697?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02816697 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.